<DOC>
	<DOCNO>NCT00868582</DOCNO>
	<brief_summary>The Centers Medicare &amp; Medicaid Services ( CMS ) , Federal agency administers Medicare program , pay positron emission tomography ( PET ) scan patient cancer certain reason certain type cancer . This study develop help CMS determine pay PET scan additional reason additional type cancer . In order collect information need decide type cancer cover Medicare , CMS provide payment otherwise non-covered PET scan patient properly register National Oncologic PET Registry ( NOPR ) . This information analyze determine effect PET scan way physician plan treat patient .</brief_summary>
	<brief_title>The National Oncologic PET Registry</brief_title>
	<detailed_description>The National Oncologic PET Registry ( NOPR ) develop response Centers Medicare &amp; Medicaid Services ( CMS ) proposal expand coverage positron emission tomography F-18 fluorodeoxyglucose ( FDG-PET ) include cancer indication presently eligible Medicare reimbursement . Under coverage evidence development ( CED ) program , Medicare reimbursement cancer obtain patient 's refer physician provider submit data clinical registry assess impact PET cancer patient management . The NOPR implement registry CMS . The NOPR sponsor World Molecular Imaging Society ( formerly Academy Molecular Imaging ) , manage American College Radiology American College Radiology Imaging Network . The original goal National Oncologic PET Registry ass effect positron emission tomography F-18 fluorodeoxyglucose ( FDG-PET ) refer physician ' plan intend patient management cancer indication currently eligible reimbursement CMS . Data collect refer physician PET study . If complete timely data report NOPR within 30 day PET scan , PET facility interpret physician ( nuclear physician/radiologist ) eligible reimbursement CMS . Based part data obtain NOPR , CMS expand coverage FDG-PET patient cancer April 3 , 2009 expand coverage June 11 , 2013 . Specifically , June 11 , 2013 , CMS issue final decision memorandum end prospective data collection requirement CED oncologic indication FDG-PET . Overall accrual FDG-PET registry nearly 288,000 scan . On February 26 , 2010 , CMS announce decision cover use NaF-18 PET identify bone metastasis . Under new policy , use NaF-18 PET would cover approve ( CED ) program . The NOPR obtain CMS approval develop registry NaF-18 amendment then-existing NOPR FDG-PET . The NaF-18 PET registry component NOPR activate accrual February 7 , 2011 . Estimated total accrual NaF-PET registry 45,000 case . As registry FDG-PET , goal NaF-18 PET registry component assess impact image examination refer physician ' plan intend management patient know suspected osseous metastatic disease . Data collect refer physician PET study , well interpret physician . If complete timely data report NOPR within 30 day PET scan , PET facility interpret physician ( nuclear physician/radiologist ) eligible reimbursement CMS .</detailed_description>
	<criteria>All Medicare beneficiary refer NaF18 PET identify bone metastasis eligible include NOPR . NaF18 PET ( nononcologic ) indication . NaF18 PET perform part clinical trial approve CMS .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Patients proven suspect cancer refer NaF-18 PET identify bone metastasis</keyword>
</DOC>